OBJECTIVES: Staphylococcus aureus bloodstream infection is associated with considerable mortality. Experimental models suggest a direct antistaphylococcal effect of acetylsalicylic acid, but evidence from human studies is scarce. We aimed to estimate the effect of low-dose acetylsalicylic acid therapy on mortality in bloodstream infections caused by S. aureus compared with Escherichia coli. DESIGN: Retrospective cohort study based on observational data from 838 and 602 episodes of S. aureus and E. coli bloodstream infection, respectively. SETTING: Swiss tertiary referral center. PATIENTS: Adult patients with S. aureus and E. coli bloodstream infection, respectively, categorized according to low-dose acetylsalicylic acid therapy as outpatient or inpatient before bacteremia. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Thirty-day all-cause mortality was analyzed in a total of 314 propensity score-matched S. aureus bloodstream infection and in 268 E. coli bloodstream infection patients, respectively (1:1 match of low-dose acetylsalicylic acid users and nonusers). S. aureus bloodstream infection cases and controls were equally matched for relevant confounders except treatment with statins, which was strongly associated with a low-dose acetylsalicylic acid use (p < 0.001). At day 30, 12.1% of cases and 27.4% of controls had died (hazard ratio, 0.40; p < 0.001). Low-dose acetylsalicylic acid use was associated with a reduced 30-day all-cause mortality in multivariate analysis (hazard ratio, 0.38; 95% CI, 0.21-0.69; p = 0.001) of matched patients and also of the entire cohort (n = 689) after adjustment for the propensity score (hazard ratio, 0.58, 95% CI, 0.34-0.98; p = 0.04). In contrast, low-dose acetylsalicylic acid use was not associated with the primary endpoint in patients with E. coli bloodstream infection (hazard ratio, 0.78; 95% CI, 0.40-1.55; p = 0.8). CONCLUSIONS: Low-dose acetylsalicylic acid at the time of bloodstream infection was strongly associated with a reduced short-term mortality in patients with S. aureus bloodstream infection. Future studies are required to investigate if early low-dose acetylsalicylic acid is a suitable treatment in patients with S. aureus bloodstream infection.
OBJECTIVES: Staphylococcus aureus bloodstream infection is associated with considerable mortality. Experimental models suggest a direct antistaphylococcal effect of acetylsalicylic acid, but evidence from human studies is scarce. We aimed to estimate the effect of low-dose acetylsalicylic acid therapy on mortality in bloodstream infections caused by S. aureus compared with Escherichia coli. DESIGN: Retrospective cohort study based on observational data from 838 and 602 episodes of S. aureus and E. coli bloodstream infection, respectively. SETTING: Swiss tertiary referral center. PATIENTS: Adult patients with S. aureus and E. coli bloodstream infection, respectively, categorized according to low-dose acetylsalicylic acid therapy as outpatient or inpatient before bacteremia. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Thirty-day all-cause mortality was analyzed in a total of 314 propensity score-matched S. aureus bloodstream infection and in 268 E. coli bloodstream infectionpatients, respectively (1:1 match of low-dose acetylsalicylic acid users and nonusers). S. aureus bloodstream infection cases and controls were equally matched for relevant confounders except treatment with statins, which was strongly associated with a low-dose acetylsalicylic acid use (p < 0.001). At day 30, 12.1% of cases and 27.4% of controls had died (hazard ratio, 0.40; p < 0.001). Low-dose acetylsalicylic acid use was associated with a reduced 30-day all-cause mortality in multivariate analysis (hazard ratio, 0.38; 95% CI, 0.21-0.69; p = 0.001) of matched patients and also of the entire cohort (n = 689) after adjustment for the propensity score (hazard ratio, 0.58, 95% CI, 0.34-0.98; p = 0.04). In contrast, low-dose acetylsalicylic acid use was not associated with the primary endpoint in patients with E. coli bloodstream infection (hazard ratio, 0.78; 95% CI, 0.40-1.55; p = 0.8). CONCLUSIONS: Low-dose acetylsalicylic acid at the time of bloodstream infection was strongly associated with a reduced short-term mortality in patients with S. aureus bloodstream infection. Future studies are required to investigate if early low-dose acetylsalicylic acid is a suitable treatment in patients with S. aureus bloodstream infection.
Authors: James Trauer; Stephen Muhi; Emma S McBryde; Shmeylan A Al Harbi; Yaseen M Arabi; Andrew J Boyle; Rodrigo Cartin-Ceba; Wei Chen; Yung-Tai Chen; Marco Falcone; Ognjen Gajic; Jack Godsell; Michelle Ng Gong; Daryl Kor; Wolfgang Lösche; Daniel F McAuley; Hollis R O'Neal; Michael Osthoff; Gordon P Otto; Maik Sossdorf; Min-Juei Tsai; Juan C Valerio-Rojas; Tom van der Poll; Francesco Violi; Lorraine Ware; Andreas F Widmer; Maryse A Wiewel; Johannes Winning; Damon P Eisen Journal: Crit Care Med Date: 2017-11 Impact factor: 7.598
Authors: Josh Sun; Satoshi Uchiyama; Joshua Olson; Yosuke Morodomi; Ingrid Cornax; Nao Ando; Yohei Kohno; May M T Kyaw; Bernice Aguilar; Nina M Haste; Sachiko Kanaji; Taisuke Kanaji; Warren E Rose; George Sakoulas; Jamey D Marth; Victor Nizet Journal: Sci Transl Med Date: 2021-03-24 Impact factor: 19.319
Authors: Christian Schoergenhofer; Eva-Luise Hobl; Michael Schwameis; Georg Gelbenegger; Thomas Staudinger; Gottfried Heinz; Walter S Speidl; Christian Zauner; Birgit Reiter; Irene Lang; Bernd Jilma Journal: Eur J Clin Invest Date: 2017-06-20 Impact factor: 4.686
Authors: Jan A Roth; Andreas F Widmer; Sarah Tschudin-Sutter; Marc Dangel; Reno Frei; Manuel Battegay; Balthasar L Hug Journal: PLoS One Date: 2017-04-17 Impact factor: 3.240
Authors: Kristján G Rögnvaldsson; Agnar Bjarnason; Karl Kristinsson; Hörður T Bragason; Helga Erlendsdóttir; Guðmundur Þorgeirsson; Magnús Gottfreðsson Journal: J Intern Med Date: 2022-03-30 Impact factor: 13.068
Authors: Antoine Dewitte; Sébastien Lepreux; Julien Villeneuve; Claire Rigothier; Christian Combe; Alexandre Ouattara; Jean Ripoche Journal: Ann Intensive Care Date: 2017-12-01 Impact factor: 6.925
Authors: Jesper Smit; Michael Dalager-Pedersen; Kasper Adelborg; Achim J Kaasch; Reimar W Thomsen; Trine Frøslev; Henrik Nielsen; Henrik C Schønheyder; Henrik T Sørensen; Christopher V Desimone; Daniel C Desimone; Mette Søgaard Journal: Open Forum Infect Dis Date: 2019-09-20 Impact factor: 3.835